D
eFFECTOR Therapeutics, Inc. EFTR
$0.0002 $0.000.00%
Recommendation
Sell
Prev Close
$0.0002
Volume
372
Avg Vol (90D)
4,266
Market Cap
$940.00
Dividend & Yield
--
52-Week Range
$0.00 - $2.95
P/E (TTM)
0.00
EPS (TTM)
-$13.32
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
6/26/2024 - InvestorPlace
Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%
6/24/2024 - Benzinga
The end of eFFECTOR Therapeutics: Oncology biotech winds down after mid-stage fail
6/24/2024 - FierceBiotech.com - Biotech
eFFECTOR Therapeutics to wind down operations, expects to be delisted from Nasdaq
6/24/2024 - Seeking Alpha - Healthcare
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
6/24/2024 - Globe Newswire
Short Interest in eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Drops By 13.7%
6/3/2024 - Zolmax
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Sees Large Drop in Short Interest
6/3/2024 - Ticker Report
eFfector Therapeutics to collaborate with Dana-Farber Cancer Institute
5/20/2024 - The Fly
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
5/20/2024 - Globe Newswire
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
5/10/2024 - InvestorPlace
eFfector Therapeutics reports Q1 EPS ($2.16), consensus ($2.16)
5/9/2024 - The Fly
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/9/2024 - Globe Newswire
Head to Head Survey: eFFECTOR Therapeutics (NASDAQ:EFTR) vs. COMPASS Pathways (NASDAQ:CMPS)
4/25/2024 - Zolmax
Analyzing eFFECTOR Therapeutics (NASDAQ:EFTR) and Qilian International Holding Group (NASDAQ:QLI)
4/19/2024 - Zolmax
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Sees Large Growth in Short Interest
4/17/2024 - Ticker Report
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
4/9/2024 - Globe Newswire
Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), uniQure (QURE) and eFFECTOR Therapeutics (EFTR)
4/9/2024 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$32.59M
EBIT (TTM)
-$32.70M
Net Income (TTM)
-$34.63M
Balance Sheet
Total Assets (Q)
$27.13M
Total Debt (Q)
$20.25M
Total Liabilities (Q)
$26.30M
Book Value Per Share (Q)
$0.2119
Cash Flow
Cash from Operations (TTM)
-$29.19M
Cash from Investing (TTM)
-$864.00K
Cash from Financing (TTM)
$35.25M
Net Change in Cash (TTM)
$5.20M
Filings
Filing Date
Thursday, May 9, 2024
Period Date
Sunday, March 31, 2024
Next Filing
(est)
Price History
Loading...
Beta
-74.08
7-Day Total Return
0.00%
30-Day Total Return
0.00%
60-Day Total Return
0.00%
90-Day Total Return
0.00%
Year to Date Total Return
--
1-Year Total Return
-99.99%
2-Year Total Return
-100.00%
3-Year Total Return
-100.00%
5-Year Total Return
--
52-week Low
Jan 02, 2025 - $0.00
52-week High
Apr 05, 2024 - $2.95
Valuation
Market Cap
$940.00 - Nano Cap
Enterprise Value
-$5.13M
Price/Sales (TTM)
--
Price/Book (Q)
0.00
Dividends and Shares
Shares Outstanding
4.08M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
effector.com
Phone Number
858 925 8215
Address
142 North Cedros Avenue
Solana Beach, CA 92075
Country
United States
Year Founded
2012
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product... more
OTC PK 04/07/2025 3:15PM Eastern Quotes delayed
Weiss Ratings